Co-Irbesso is a fixed-dose combination of an angiotensin-II receptor antagonist – irbesartan, and a thiazide diuretic – hydrochlorothiazide. The combination of these two ingredients has an additive antihypertensive effect which reduces blood pressure to a greater degree than either component alone.
Co-Irbesso is indicated:
– for treatment of essential hypertension;
– in adult patients whose blood pressure is not adequately controlled on irbesartan or hydrochlorothiazide alone.
Subject to medical prescription.
Concentrations and pharmaceutical form: 150 mg/12.5 mg, 300 mg/12.5 mg film-coated tablets